🏢 官网IRMIRMDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 04:01:00(美东 10-21 16:01)·⟳ 抓取 04:05:42回填·⚡ 决策 10-22 04:06:51·5.7 天前
Mirum Pharmaceuticals公告将出席11月三场投资者会议，纯例行路演安排无增量信息
公告仅为11月三场投资者会议的出席日程与网播安排，无数据读出、指引、融资、合作等新增事实；会议在3周后举行，当下没有可定价的edge，属典型的日历型IR噪音。
📄 原文MIRM↗ 原文
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, toda…
不做 Mirum Pharmaceuticals, Inc.（MIRM.US）
纯例行投资者会议出席公告（11月10/11/17日Wolfe/Stifel/Jefferies），无临床数据、监管、指引、融资或合作等任何增量事实；会议距今约3周，当下无可定价edge，等待会议现场出现实质信息后再研判
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Mirum公告11月出席Wolfe/Stifel/Jefferies三场医疗会议，仅是路演日程通知，无任何基本面增量，不构成交易催化；若会议上释放新信息应在11月10日起另行研判。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 low · price-in 风险 low ↗
主要风险
- 会议（最早11月10日）现场若披露voliximat、brelovitug等管线新数据或指引变化，可能构成独立催化，届时需重新研判，不能提前基于日程交易
先例如何影响了这次决策
对本次决策的影响:先例与机制分析一致支持AVOID，未产生任何交易腿
方向:无可对照的定价先例；例行会议出席公告在生物科技板块通常不产生事件后超额收益，近期ANTX、Satellos同类公告均被判为不做
涨幅量级:无高相似先例可校准幅度，且事件本身无增量，不适用tp/sl
形态:同臂近24小时内ANTX（10-20）与Satellos（10-21）的同类'出席11月医疗会议'公告均判定无催化、不做，模式一致
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 4,679 ms
{"result": "search_processed_events:agent query=`mirm fireside chat november 2026 conference participation | mirum pharmaceuticals investor conferences wolfe stifel jefferies 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.9/72 小时、26691 条本臂决策(完整)，返回 2 条候选。\n• 10-20 20:22 UTC(北京 10-21 04:22) [bm25:50%] 不做 ANTX.US
原文全文
展开原文 · 2,325 字
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences:
Wolfe Research Healthcare Conference 2026
:
Tuesday, November 10, 2026
Company fireside chat starting at 8:00 a.m. ET
Stifel 2026 Healthcare Conference
: Wednesday, November 11, 2026
Company fireside chat starting at 1:20 p.m. ET
2026 Jefferies Global Healthcare Conference
: Tuesday, November 17, 2026
Company presentation starting at 12:30 p.m. GMT
The presentation and fireside chats will be webcast live and can be accessed by visiting the
Investors
section of Mirum’s corporate website. The archived webcasts will be available for replay.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis
(PFIC),
ATEBRIOZ™ (zilurgisertib) for fibrodysplasia ossificans progressiva (FOP), CHOLBAM® (cholic acid) for bile-acid synthesis disorders and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).
Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).
Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at
www.mirumpharma.com
and follow Mirum on
Facebook
,
LinkedIn
,
Instagram
and
X
.
Investor Contact:
Andrew McKibben
ir@mirumpharma.com
Media Contact:
Meredith Kiernan
media@mirumpharma.com
Source: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences:
Wolfe Research Healthcare Conference 2026
:
Tuesday, November 10, 2026
Company fireside chat starting at 8:00 a.m. ET
Stifel 2026 Healthcare Conference
: Wednesday, November 11, 2026
Company fireside chat starting at 1:20 p.m. ET
2026 Jefferies Global Healthcare Conference
: Tuesday, November 17, 2026
Company presentation starting at 12:30 p.m. GMT
The presentation and fireside chats will be webcast live and can be accessed by visiting the
Investors
section of Mirum’s corporate website. The archived webcasts will be available for replay.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis
(PFIC),
ATEBRIOZ™ (zilurgisertib) for fibrodysplasia ossificans progressiva (FOP), CHOLBAM® (cholic acid) for bile-acid synthesis disorders and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).
Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).
Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at
www.mirumpharma.com
and follow Mirum on
,
,
and
X
.
Investor Contact:
Andrew McKibben
ir@mirumpharma.com
Media Contact:
Meredith Kiernan
media@mirumpharma.com
Source: Mirum Pharmaceuticals, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
2d449b7c65· 2026-10-22 04:06 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前